Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal
Corcept Therapeutics Inc. · PHARMACEUTICAL PREPARATIONS · Now $70.44
+24% in 7d after detection
Post-detection moves
1h
—
1d
+5.6%
3d
+8.3%
7d
+24%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS